Targeting T-cell malignancies using allogeneic double-negative CD4-CAR-T cells

BACKGROUND: Patients with relapsed/refractory T-cell malignancies have limited treatment options. The use of chimeric antigen receptor (CAR)-T cell therapy for T-cell malignancies is challenging due to possible blast contamination of autologous T-cell products and fratricide of CAR-T cells targeting...

Descripción completa

Detalles Bibliográficos
Autores principales: Fang, Karen Kai-Lin, Lee, Jongbok, Khatri, Ismat, Na, Yoosu, Zhang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10496713/
https://www.ncbi.nlm.nih.gov/pubmed/37678917
http://dx.doi.org/10.1136/jitc-2023-007277

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10496713/
https://www.ncbi.nlm.nih.gov/pubmed/37678917
http://dx.doi.org/10.1136/jitc-2023-007277

Ejemplares similares